M Sánchez-Díaz, Á Flórez, M Ara-Martín, S Arias-Santiago, R Botella-Estrada, J Cañueto, G Carretero-Hernández, P Coto-Segura, E de Eusebio-Murillo, F J García-Latasa de Araníbar, V García-Patos Briones, J Gardeazabal García, C Gómez-Fernández, S Hernández-Ostiz, R Izu Belloso, A López-Ávila, P Manchado López, A Martín-Santiago, I Martinez De Espronceda Ezquerro, A Mateu-Puchades, P Mercader-García, J Notario Rosa, L Palacio Aller, C Pérez-Hortet, L Quintana-Castanedo, R Rivera, V Rocamora Duran, I M Rodríguez-Nevado, R Ruiz-Villaverde, J Suárez, L Trasobares-Marugán, C Vizán-de Uña, I Yanguas, A Zulaica-Garate, I García-Doval, M Á Descalzo, M Grau-Pérez, J M Carrascosa-Carrillo
BACKGROUND AND OBJECTIVE: Although the Spanish Ministry of Health prepares national therapeutic positioning reports (TPRs) and drug reimbursement policies, each of the country's 17 autonomous communities is responsible for health care services and prescription requirements in its territory. The aim of the EQUIDAD study was to describe and explore potential differences in prescription requirements for new dermatology drugs across the autonomous communities. MATERIAL AND METHODS: Cross-sectional study conducted in April and May, 2023...
October 25, 2023: Actas Dermo-sifiliográficas